Objectives: TrialNet's goal to test preventions for type 1 diabetes has created an opportunity
to gain new insights into the natural history of pre‐type 1 diabetes. The TrialNet Natural …

To evaluate the emergence of diabetes-associated autoantibodies in young children and to
assess whether such antibodies can be used as surrogate markers of type 1 diabetes in …

Early onset type 1 diabetes is associated with rapid β-cell failure and high levels of HLA-
mediated genetic susceptibility. We examined familial risk of disease in relation to age at …

Aims/hypothesis We assessed the utility of the OGTT and random plasma glucose
concentrations in predicting the time to diagnosis of type 1 diabetes. Methods A population …

General childhood population-based screening for risk of T1D will allow detection of an at-
risk population that can participate in natural history studies to better understand disease …

Primary prevention of type 1 diabetes (T1D) requires intervention in genetically at‐risk
infants. The Global Platform for the Prevention of Autoimmune Diabetes (GPPAD) has …

Aims/hypothesis To compare the predictive characteristics of autoantibodies to GAD (GADA)
and islet antigen 2 (IA–2A) for type 1 diabetes between siblings of affected children and …

When making predictions, a number of specific assumptions should be noted from the very
start. First, what is true of the past may not be true for the future. For example, type 1 diabetes …

OBJECTIVE We assessed the accuracy of the Diabetes Prevention Trial–Type 1 Risk Score
(DPTRS), developed from the Diabetes Prevention Trial–Type 1 (DPT-1), in the TrialNet …

Type 1 diabetes (T1D) is an autoimmune disease with a prolonged and variable latent
period that culminates in the destruction of pancreatic β-cells and the development of …